MENLO PARK, Calif., July 25, 2013 /PRNewswire/ -- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced it has entered into a strategic partnership with the Valencia Infertility Institute (IVI), a global leader in reproductive medicine with 23 clinics throughout the world.
Under the terms of this multi-year agreement, Auxogyn will install its Early Embryo Viability Assessment (Eeva™) systems at IVI clinics to support two Auxogyn-led research initiatives: the Eeva Pregnancy Investigational Clinical (EPIC) Study and an aneuploidy research program. IVI will use the Eeva systems to treat at least 200 patients participating in the EPIC Study in Europe, which will evaluate the impact on clinical pregnancy rates of improved embryo selection with the Eeva Test. This partnership will also support Auxogyn's current aneuploidy (an abnormal number of chromosomes) research programs, which – by leveraging the Eeva system – could lead to the development of non-invasive, automated methods for aneuploidy screening.
"Auxogyn is very pleased to collaborate with IVI, which has one of the world's largest networks of IVF clinics and a proven track record of promoting clinical and scientific progress through cutting-edge research," stated Lissa Goldenstein, President and CEO of Auxogyn. "Through this partnership, we're accelerating our growth in Europe and advancing our mission of improving outcomes for patients undergoing IVF."
Installation of the Eeva systems at IVI clinics in Spain is scheduled to occur in August 2013. These will be the first clinics in Spain to offer this innovative technology to eligible patients who enroll in the Auxogyn research studies.
"IVI prides itself on leveraging new approaches to offer patients the latest treatment options to achieve the best results," stated Dr. Antonio Pellicer, founder of IVI. "We look forward to partnering with Auxogyn on important research that offers new hope to our patients and advances the reproductive medicine field."
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective information regarding embryo viability that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information visit www.auxogyn.com and follow us on Twitter @Auxogyn.
About the Early Embryo Viability Assessment (Eeva™) Test
The Eeva Test provides IVF clinicians with predictive information about the embryo's development potential to help improve embryo selection. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters conceived by researchers at Stanford University in the US. With results from the Eeva Test, IVF teams now have predictive and objective information to combine morphological assessment to help improve the embryo selection decision. The Eeva Test was validated in a prospective, multi-centre, 54-patient clinical trial with 755 embryos. Embryologists using Eeva results were significantly able to improve their ability to identify non-viable embryos relative to traditional methods alone. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were initially presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.
Eeva is currently CE Marked and available for use in the EU and is pending FDA clearance in the United States. For a full list of clinics in the EU offering the Eeva Test please visit www.eevaivf.com or follow us on Twitter @EevaIVF.
About IVI Spain
IVI was created in 1990 as the first medical institution in Spain to specialise entirely in Human Reproduction. Since then, it has helped more than 55,000 babies to be born thanks to its use of the newest assisted reproduction methods. At IVI clinics we carry out all of the assisted reproduction techniques that are currently available, and it is one of the European centres with the best pregnancy rates; in fact, 9 out of 10 couples who come to IVI because of fertility problems manage to achieve their goal. IVI currently has 23 clinics in 7 countries, and is a leader in reproductive medicine. For more information visit www.ivi.es.
SOURCE Auxogyn, Inc.